Enclave Advisors LLC Buys 2,612 Shares of Danaher Corporation $DHR

Enclave Advisors LLC lifted its stake in shares of Danaher Corporation (NYSE:DHR) by 104.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,102 shares of the conglomerate’s stock after buying an additional 2,612 shares during the quarter. Enclave Advisors LLC’s holdings in Danaher were worth $1,130,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DHR. Marquette Asset Management LLC raised its stake in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 73 shares during the period. N.E.W. Advisory Services LLC purchased a new position in shares of Danaher in the second quarter valued at $25,000. Main Street Group LTD purchased a new position in shares of Danaher in the first quarter valued at $25,000. Field & Main Bank acquired a new stake in Danaher during the 2nd quarter valued at $29,000. Finally, Evolution Wealth Management Inc. grew its holdings in Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.9%

Danaher stock opened at $223.30 on Wednesday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm has a market cap of $156.98 billion, a PE ratio of 39.66, a P/E/G ratio of 2.78 and a beta of 0.76. The firm’s 50 day moving average price is $212.41 and its two-hundred day moving average price is $195.13.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.77 EPS. On average, research analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DHR. Barclays boosted their price target on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Saturday. TD Cowen increased their price objective on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Royal Bank Of Canada boosted their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.